Format

Send to

Choose Destination
Bioorg Med Chem. 2009 Nov 1;17(21):7457-64. doi: 10.1016/j.bmc.2009.09.022. Epub 2009 Sep 18.

Structure-based drug design identifies novel LPA3 antagonists.

Author information

1
Department of Chemistry and Computational Research on Materials Institute, The University of Memphis, Memphis, TN 38152, United States.

Abstract

Compound 5 ([5-(3-nitrophenoxy)-1,3-dioxo-1,3-dihydro-2-isoindol-2-yl]acetic acid) was identified as a weak selective LPA(3) antagonist (IC(50)=4504 nM) in a virtual screening effort to optimize a dual LPA(2 and 3) antagonist. Structure-based drug design techniques were used to prioritize similarity search matches of compound 5. This strategy rapidly identified 10 novel antagonists. The two most efficacious compounds identified inhibit activation of the LPA(3) receptor by 200 nM LPA with IC(50) values of 752 nM and 2992 nM. These compounds additionally define changes to our previously reported pharmacophore that will improve its ability to identify more potent and selective LPA(3) receptor antagonists. The results of the combined computational and experimental screening are reported.

PMID:
19800804
PMCID:
PMC2771199
DOI:
10.1016/j.bmc.2009.09.022
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center